Arcutis Biotherapeutics, Inc. (ARQT) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Westlake Village, CA, United States. El CEO actual es Todd Franklin Watanabe.
ARQT tiene fecha de IPO 2020-01-31, 342 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $3.11B.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company headquartered in Westlake Village, California, specializing in the development and commercialization of innovative treatments for dermatological diseases. The company's lead product candidate, ARQ-151, is a topical roflumilast cream that has completed Phase III clinical trials for plaque psoriasis and atopic dermatitis. Arcutis is advancing a robust pipeline that includes ARQ-154 for seborrheic dermatitis and scalp psoriasis, ARQ-252, a selective topical Janus kinase type 1 inhibitor for hand eczema and vitiligo, and ARQ-255, a deeper-penetrating topical formulation designed to treat alopecia areata. The company was incorporated in 2016 and rebranded as Arcutis Biotherapeutics in 2019.
